Spinocerebellar ataxias (SCAs) are neurodegenerative disorders characterized by predominant atrophy of the cerebellum and pons, with the main symptom being ataxia. There is currently no treatment for this disorder due to the lack of robust biomarkers to evaluate the disease progression. This study aimed to identify robust biomarkers for this disorder using a combination of magnetic resonance spectroscopy and imaging techniques. This study confirmed neurometabolic alterations in SCAs as well as microstructural modifications resulting from the disease. This study also showed that imaging biomarkers are more sensitive to disease progression than clinical scores.